(Q87467570)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24642799%20AND%20SRC:MED&resulttype=core&format=json

11 March 2020

review article

1 reference

title

Renal involvement in antiphospholipid syndrome (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24642799%20AND%20SRC:MED&resulttype=core&format=json

antiphospholipid syndrome

11 March 2020

main subject

1 reference

3

Munther Khamashta

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24642799%20AND%20SRC:MED&resulttype=core&format=json

11 March 2020

author name string

Savino Sciascia

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24642799%20AND%20SRC:MED&resulttype=core&format=json

11 March 2020

Maria José Cuadrado

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24642799%20AND%20SRC:MED&resulttype=core&format=json

11 March 2020

Dario Roccatello

series ordinal

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24642799%20AND%20SRC:MED&resulttype=core&format=json

11 March 2020

publication date

18 March 2014

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24642799%20AND%20SRC:MED&resulttype=core&format=json

Nature Reviews Nephrology

11 March 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24642799%20AND%20SRC:MED&resulttype=core&format=json

11 March 2020

volume

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24642799%20AND%20SRC:MED&resulttype=core&format=json

11 March 2020

issue

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24642799%20AND%20SRC:MED&resulttype=core&format=json

11 March 2020

page(s)

279-289

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24642799%20AND%20SRC:MED&resulttype=core&format=json

Thrombosis, abortion, cerebral disease, and the lupus anticoagulant

11 March 2020

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.38

International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.38

International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS)

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.38

Epidemiology of the antiphospholipid antibody syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.38

Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.38

Task Force on Catastrophic Antiphospholipid Syndrome (APS) and Non-criteria APS Manifestations (I): catastrophic APS, APS nephropathy and heart valve lesions.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.38

Pathogenic mechanisms mediating antiphospholipid syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.38

The pathogenesis of the antiphospholipid syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.38

Vascular endothelial growth factor expression in monocytes from patients with primary antiphospholipid syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.38

GAPSS: the Global Anti-Phospholipid Syndrome Score

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.38

Antiphospholipid syndrome and the kidneys

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.38

Antiphospholipid syndrome nephropathy in patients with systemic lupus erythematosus and antiphospholipid antibodies: prevalence, clinical associations, and long-term outcome.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.38

The renal pathology of primary antiphospholipid syndrome: a distinctive form of endothelial injury

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.38

What nephrologists need to know about antiphospholipid syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.38

Thrombotic microangiopathy and associated renal disorders

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.38

Catastrophic antiphospholipid syndrome (CAPS).

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.38

The expanding spectrum of renal diseases associated with antiphospholipid syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.38

Renal involvement in primary antiphospholipid syndrome: retrospective analysis of 160 patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.38

Antiphospholipid antibodies are associated with an increased risk for chronic renal insufficiency in patients with lupus nephritis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.38

Renal artery thrombosis and hypertension in a 13 year old girl with antiphospholipid syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.38

Renal artery stenosis in the antiphospholipid (Hughes) syndrome and hypertension

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.38

Renal involvement in the antiphospholipid syndrome (APS)-APS nephropathy.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.38

Noninvasive investigation for renal artery stenosis: contrast-enhanced magnetic resonance angiography and color Doppler sonography as compared to digital subtraction angiography

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.38

Imaging modalities for renal artery stenosis in suspected renovascular hypertension: prospective intraindividual comparison of color Doppler US, CT angiography, GD-enhanced MR angiography, and digital substraction angiography

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.38

Primary antiphospholipid syndrome presenting as renal vein thrombosis and membranous nephropathy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.38

Comparison of renal disease severity and outcome in patients with primary antiphospholipid syndrome, antiphospholipid syndrome secondary to systemic lupus erythematosus (SLE) and SLE alone

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.38

Renal transplantation in lupus nephritis: a Brazilian cohort

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.38

Bilateral renal infarction in a lupus patient: an unusual pathology

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.38

Renal infarction and thrombosis of the infrarenal aorta in a 35-year-old man with primary antiphospholipid syndrome.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.38

[Renal infarction in systemic lupus with antiphospholipid syndrome: role of hydroxychloroquine withdrawal? Comment on the article by Szymezak et al]

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.38

Antibodies to endothelial cells in borderline hypertension

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.38

Antiphospholipid antibodies and hypertension

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.38

Malignant hypertension and antiphospholipid syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.38

Risk factors for a first thrombotic event in antiphospholipid antibody carriers: a prospective multicentre follow-up study.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.38

Antiphospholipid antibodies and renal outcomes in patients with lupus nephritis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.38

IgM anti-β2 glycoprotein I is protective against lupus nephritis and renal damage in systemic lupus erythematosus

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.38

Association of anticardiolipin antibodies with intraglomerular thrombi and renal dysfunction in lupus nephritis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.38

The management of thrombosis in the antiphospholipid-antibody syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.38

Association of thrombotic microangiopathy and intimal hyperplasia with bleeding post-renal biopsy in antiphospholipid antibody-positive patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.38

Endstage renal failure in primary antiphospholipid syndrome--case report and review of literature

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.38

Ten-yr renal allograft survival of patients with antiphospholipid antibody syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.38

Kidney disease in antiphospholipid syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.38

Frequent hemodialysis graft thrombosis: association with antiphospholipid antibodies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.38

Anticardiolipin antibodies and lupus anticoagulant in end-stage renal disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.38

Increased incidence of antiphospholipid antibodies in left ventricular assist system recipients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.38

Anticardiolipin antibodies in patients on regular hemodialysis: an epiphenomenon?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.38

Management of end-stage renal disease patients with antiphospholipid antibody syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.38

beta 2-Glycoprotein I-dependent and-independent anticardiolipin antibody in patients with end-stage renal disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.38

Anticardiolipin antibodies and lupus anticoagulant in patients treated with different methods of renal replacement therapy in comparison to patients with systemic lupus erythematosus

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.38

Prevalence of lupus anticoagulant and anticardiolipin antibodies in haemodialysis patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.38

The relationship between anticardiolipin antibodies and vascular access occlusion in patients on hemodialysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.38

Incidence of arteriovenous thrombosis and the role of anticardiolipin antibodies in hemodialysis patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.38

Association of anticardiolipin antibodies with vascular access occlusion in hemodialysis patients: cause or effect?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.38

Anticardiolipin antibody in patients on maintenance hemodialysis and its association with recurrent arteriovenous graft thrombosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.38

Are antiphospholipid antibodies clinically relevant in dialysis patients?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.38

End-stage renal disease from glomerulonephritis associated with anti-phospholipid syndrome.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.38

IgA antibodies against β2 glycoprotein I in hemodialysis patients are an independent risk factor for mortality

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.38

The clinical relevance of IgA anticardiolipin and IgA anti-β2 glycoprotein I antiphospholipid antibodies: a systematic review

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.38

Antiphospholipid antibody syndrome in renal transplantation: occurrence of clinical events in 96 consecutive patients with systemic lupus erythematosus

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.38

Antiphospholipid antibodies are a risk factor for early renal allograft failure: isolation of antiphospholipid antibodies from a thrombosed renal allograft

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.38

Antiphospholipid antibodies are a risk factor for early renal allograft failure

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.38

Antiphospholipid antibodies and renal transplantation: a risk assessment

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.38

Prevalence and clinical significance of antiphospholipid antibodies in renal transplant recipients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.38

Morphology of vascular, renal, and heart lesions in the antiphospholipid syndrome: relationship to pathogenesis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.38

Severe vascular lesions and poor functional outcome in kidney transplant recipients with lupus anticoagulant antibodies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.38

Clinical significance of antiphospholipid antibodies on allograft and patient outcome after kidney transplantation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.38

A Systematic Review and Meta-Analysis of Pregnancy Outcomes in Patients with Systemic Lupus Erythematosus and Lupus Nephritis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.38

Nephrological and obstetric complications of the antiphospholipid syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.38

Post-partum bilateral renal cortical necrosis in antiphospholipid syndrome and systemic lupus erythematosus.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.38

The challenge of pregnancy for patients with SLE.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.38

Catastrophic antiphospholipid syndrome - 20 years later

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.38

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.38

Catastrophic antiphospholipid syndrome (CAPS): descriptive analysis of a series of 280 patients from the "CAPS Registry".

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.38

Lessons from the catastrophic antiphospholipid syndrome (CAPS) registry

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.38

Evidence-based recommendations for the prevention and long-term management of thrombosis in antiphospholipid antibody-positive patients: report of a task force at the 13th International Congress on antiphospholipid antibodies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.38

14th International Congress on Antiphospholipid Antibodies: task force report on antiphospholipid syndrome treatment trends

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.38

Incidence of a first thromboembolic event in asymptomatic carriers of high-risk antiphospholipid antibody profile: a multicenter prospective study.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.38

Clinical accuracy for diagnosis of antiphospholipid syndrome in systemic lupus erythematosus: evaluation of 23 possible combinations of antiphospholipid antibody specificities

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.38

Primary prevention in antiphospholipid antibody carriers

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.38

Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.38

Management of refractory anti-phospholipid syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.38

Antiphospholipid syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.38

A reversible bilateral renal artery stenosis in association with antiphospholipid syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.38

Renal artery stenosis in hypertensive patients with antiphospholipid (Hughes) syndrome: outcome following anticoagulation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.38

Hydroxychloroquine use is associated with lower odds of persistently positive antiphospholipid antibodies and/or lupus anticoagulant in systemic lupus erythematosus

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.38

Treatment-induced downregulation of antiphospholipid antibodies: effect of rituximab alone on clinical and laboratory features of antiphospholipid syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.38

Renal involvement in primary antiphospholipid syndrome and its response to immunosuppressive therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.38

Use of new oral anticoagulants in antiphospholipid syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.38

A new dawn of anticoagulation for patients with antiphospholipid syndrome?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.38

A pilot open-label phase II trial of rituximab for non-criteria manifestations of antiphospholipid syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.38

Eculizumab and renal transplantation in a patient with catastrophic antiphospholipid syndrome: effect of heparin on complement activation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2014.38

Thrombosis in systemic lupus erythematosus. Relation to the presence of circulating anticoagulants

31 March 2020

1 reference

12 December 2020

Hypertension and the antiphospholipid antibodies

1 reference

12 December 2020

IgM anticardiolipin antibodies are associated with stenosis of vascular access in hemodialysis patients but do not predict thrombosis

1 reference

12 December 2020

Anticardiolipin antibodies in hemodialysis patients with hepatitis C and their role in fistula failure.

1 reference

12 December 2020

Lack of association between antiphospholipid antibody and WHO classification in lupus nephritis

1 reference

12 December 2020

Lupus anticoagulant associated with renal thrombotic microangiopathy and pregnancy-related renal failure

1 reference

12 December 2020

[Antiphospholipid antibodies in systemic lupus erythematosus: incidence, significance and relation to lupus nephritis]

1 reference

12 December 2020

Hypertension, renal artery stenosis and the "primary" antiphospholipid syndrome

1 reference

12 December 2020

Prevention of thrombosis relapse in antiphospholipid syndrome patients refractory to conventional therapy using intravenous immunoglobulin.

1 reference

12 December 2020

Antiphospholipid syndrome nephropathy in systemic lupus erythematosus.

1 reference

12 December 2020

Bilateral renal artery occlusion in a patient with primary antiphospholipid antibody syndrome: thrombosis, vasculitis or both?

1 reference

12 December 2020

Vasculitis in the antiphospholipid syndrome: culprit or consort?

1 reference

12 December 2020

Antiphospholipid syndrome (APS) nephropathy in catastrophic, primary, and systemic lupus erythematosus-related APS.

1 reference

12 December 2020

Malignant hypertension in antiphospholipid syndrome without overt lupus nephritis

1 reference

12 December 2020

New approaches for managing antiphospholipid syndrome

1 reference

12 December 2020

Repeated renal infarction in native and transplanted kidneys due to left ventricular thrombus formation caused by antiphospholipid antibody syndrome

1 reference

12 December 2020

Primary antiphospholipid syndrome: functional outcome after 10 years

1 reference

12 December 2020

[Primary antiphospholipid syndrome associated with malignant hypertension]

1 reference

12 December 2020

The intrarenal vascular lesions associated with primary antiphospholipid syndrome

1 reference

12 December 2020

[Anticardiolipin antibodies in hemodialysis patients and in renal transplant recipients: prevalence and significance]

1 reference

12 December 2020

Renal involvement in primary antiphospholipid syndrome

1 reference

12 December 2020

Reversible renal failure in the primary antiphospholipid syndrome--a report of two cases

1 reference

12 December 2020

Identifiers

DOI

10.1038/NRNEPH.2014.38

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24642799%20AND%20SRC:MED&resulttype=core&format=json

11 March 2020

1 reference